October 3, 2022

Novartis to spin off generics business Sandoz next year

Read Time:3 Minute, 40 Second

  • Co has not received formal offers for Sandoz to date
  • Announcement of spin-off not a surprise – analysts
  • Novartis shares inch lower in afternoon trading

ZURICH/LONDON, Aug 25 (Reuters) – Novartis (NOVN.S) plans to spin off its underperforming generics unit Sandoz to sharpen its focus on its patented prescription medicines, the Swiss group said on Thursday, acknowledging it had not received any formal offers for the business to date.

The company started a strategic review of Sandoz last October – examining a range of options, including retaining the business, spinning it off or selling it – following a protracted period of underperformance driven largely by mounting pricing pressures in the off-patent drug sector.

Apart from some preliminary interest, Novartis has not received any formal binding offers for Sandoz so far – but if any “highly attractive” bids did emerge Novartis would fully consider them, CEO Vas Narasimhan said in a conference call with analysts.

Register now for FREE unlimited access to Reuters.com

However, “we think a spin is by far and away the most likely and best way to separate these two companies,” he said.

The spin-off announcement did not come as a surprise given poor market conditions and the struggling broader market for generics, analysts said.

“Previous spin-outs from pharma company have created near-term excitement given the strong track record of pharma spins outperforming parents. In this case, the competitive pressures in the generic space are likely to translate into lesser near term interest,” Citi analysts wrote in a note.

Novartis shares already appropriately reflect the valuation of the two businesses, added J.P. Morgan analysts in a note.

The Basel-based company’s stock inched lower in afternoon trading.

Sandoz – which generated nearly $10 billion in sales last year selling generics and biosimilars (cheap versions of biologic drugs made from living organisms) – will emerge as Europe’s leading generics company, according to Novartis.

Narasimhan described the market for generics as “highly attractive” going forward, citing $400 billion to $500 billion worth of branded products expected to go off-patent over the coming decade.

The standalone Sandoz is expected to be headquartered in Switzerland and listed on the SIX Swiss Exchange, with an American Depositary Receipt programme in the United States. Richard Saynor would remain CEO following the spin-off.

The transaction, which is anticipated to be generally tax-neutral for Novartis, is expected to be completed in the second half of next year, subject to market conditions, tax rulings and opinions, final board endorsement and shareholder approvals, Novartis said.

Plans for the spin-off would not be derailed by U.S. drug pricing reforms, Narasimhan said.

Last week, a landmark law that included provisions to tackle the rising cost of medicines was passed in the United States, in a rare legislative defeat for the powerful pharmaceutical industry.

Sandoz will, however, reassess whether certain biosimilars still are an attractive market opportunity, added Narasimhan.

PRICING PRESSURES

Sandoz’s sales have been hurt by pricing pressure that has affected the broader generics industry for years, particularly in the United States, although the country accounts for less than a quarter of its total sales.

In 2021, sales in Europe declined by 2%, while U.S. sales tumbled 15% on a constant currency basis, hit also by a COVID-related drop in demand.

However, there are encouraging signs. Last month, Novartis said Sandoz’s earnings would likely hold steady this year, primarily thanks to growth in Europe.

Narasimhan also predicted a return to U.S. growth, with expected biosimilar approvals for blockbuster medicines such as Humira and Tysabri next year.

Novartis has been pruning its business interests, spinning off its Alcon eye care business in 2019 and last November agreeing to sell a nearly one-third voting stake in Roche (ROG.S).

It tried to divest part of Sandoz back in 2018, but a $900 million deal with India’s Aurobindo Pharma (ARBN.NS) fell foul of antitrust rules.

Now, Narasimhan is aiming to spin off the entire division, which accounted for close to a fifth of Novartis’ $51.6 billion in sales last year.

Novartis is also implementing a restructuring programme that involves cutting up to 8,000 jobs, or about 7.4% of its global workforce. read more

Register now for FREE unlimited access to Reuters.com

Reporting by Silke Koltrowitz and Natalie Grover
Editing by Mark Potter and Elaine Hardcastle

Our Standards: The Thomson Reuters Trust Principles.



Source link

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post It’s OK to say goodbye to the ‘dress rehearsal’ preseason game
Next post Viral video reinforces growing GOP political dilemma on abortion